Immuno-oncology: manufacturing and commercial business models for the new decade

CELL AND GENE THERAPY INSIGHTS

July 2020

Immuno-oncology: manufacturing and commercial business models for the new decade

Download PDF

Foreword

Immuno-oncology: manufacturing and commercial business models for the new decade – Foreword

Immuno-oncology: manufacturing and commercial business models for the new decade – Foreword

Expert Insight

Current and future directions for tumor infiltrating lymphocyte therapy for the treatment of solid tumors

Current and future directions for tumor infiltrating lymphocyte therapy for the treatment of solid tumors

M Fardis, K DiTrapani, F Graf Finckenstein et al.

Immuno-oncology cell therapies: commercial considerations and strategies for the new decade

Immuno-oncology cell therapies: commercial considerations and strategies for the new decade

Innovating CAR T cell therapy for today and tomorrow

Innovating CAR T cell therapy for today and tomorrow

Decentralized manufacturing: from stem cell transplants to the next generation of cellular immunotherapies

Decentralized manufacturing: from stem cell transplants to the next generation of cellular immunotherapies

Matthew Li, Sadik Kassim

Commercialization of TCR T-cell therapy: patient journey implications

Commercialization of TCR T-cell therapy: patient journey implications

Kimberly Freeman

Innovator Insight

Simplifying GMP CART and CAR NK cell therapy manufacturing processes

Simplifying GMP CART and CAR NK cell therapy manufacturing processes

Sarah Dluczek, Kate Fynes, Martha Luevano

Expert Roundtable Video

Expert Roundtable: evolving autologous and allogeneic cell therapy manufacturing models in the commercial setting

Expert Roundtable: evolving autologous and allogeneic cell therapy manufacturing models in the commercial setting

D Adams, G Russotti, E Fearnot et al.

Expert Roundtable

Evolving autologous and allogeneic cell therapy manufacturing models in the commercial setting

Evolving autologous and allogeneic cell therapy manufacturing models in the commercial setting

D Adams, G Russotti, E Fearnot et al.

Interview

Looking to the future of stem cell-derived immunotherapy

Looking to the future of stem cell-derived immunotherapy

Understanding the drivers of success and failure in CAR T cell therapy

Understanding the drivers of success and failure in CAR T cell therapy

Webinars

Simplifying GMP CAR-T and CAR NK cell therapy manufacturing processes

Simplifying GMP CAR-T and CAR NK cell therapy manufacturing processes

M Elia Luevano Salinas PhD, X Wang PhD, S Fricke PhD et al.

Challenges of cell collections for cell therapy manufacturing: what do we want in the bag?

Challenges of cell collections for cell therapy manufacturing: what do we want in the bag?

E Valdez RN MSN, J Beltzer, S Soni et al.

Manufacturing of endogenous, non-engineered, antigen specific T cells against tumor targets

Manufacturing of endogenous, non-engineered, antigen specific T cells against tumor targets

Ali Mohamed, Megan Ciarlo